In a significant shift within the global market landscape, Novo Nordisk experienced a sharp 10% increase in stock prices, catapulting the company to a market capitalization of $613.3 billion. This surge enabled Novo Nordisk to surpass Tesla's market cap of $560.87 billion, marking a notable achievement for the pharmaceutical giant. The company's growth was primarily fueled by the success of its obesity drug, Wegovy, demonstrating the increasing market value and investor confidence in healthcare and pharmaceutical sectors.